Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T790M mutation

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in EU

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer

Around 210,000 people worldwide are diagnosed with the disease each year

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer

Breast cancer is one of the leading causes of cancer-related deaths globally, with more than two millions cases diagnosed in 2020

- PMLiVE

AstraZeneca joins UK pilot evaluating AI-based lung cancer diagnosis system

More than 43,000 people are diagnosed with lung cancer every year in the UK

- PMLiVE

AstraZeneca’s severe asthma treatment approved in EU for self-administration

Most healthcare providers, patients and caregivers are able to successfully use the pre-filled pen

- PMLiVE

AstraZeneca and Avillion’s asthma rescue treatment granted FDA approval

Airsupra significantly reduces the risk of severe asthma exacerbations

- PMLiVE

AstraZeneca to acquire CinCor Pharma in deal worth up to $1.8bn

The deal will strengthen AZ’s cardiorenal pipeline through the addition of baxdrostat

- PMLiVE

RQ Bio-discovered antibody enters clinic as part of AstraZeneca COVID-19 study

The trial will evaluate the UK-based biotech’s AZD3152 in combination with cilgavimab

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer

The treatment has been recommended for use within a managed access arrangement

- PMLiVE

iOnctura awarded €17.5m from EIC Accelerator for novel pancreatic cancer therapy

The company dosed the first patient in a phase 1b study of IOA-289 earlier this month

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced gastric cancer

Approximately 136,000 cases of gastric cancer are diagnosed annually in Europe

- PMLiVE

Exact Sciences highlights impact of precision oncology portfolio on breast cancer treatment

Data presented at SABCS 2022 supports the company’s cancer diagnostics portfolio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links